



Published in final edited form as:

Cell Rep. 2025 February 25; 44(2): 115245. doi:10.1016/j.celrep.2025.115245.

## Structural insights into HIV-2 CA lattice formation and FG-pocket binding revealed by single-particle cryo-EM

Matthew Cook<sup>1,2</sup>, Christian Freniere<sup>1,2</sup>, Chunxiang Wu<sup>1</sup>, Faith Lozano<sup>1</sup>, Yong Xiong<sup>1,3,\*</sup>

<sup>1</sup>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA

### SUMMARY

One of the striking features of human immunodeficiency virus (HIV) is the capsid, a fullerene cone comprised of pleomorphic capsid protein (CA) that shields the viral genome and recruits cofactors. Despite significant advances in understanding the mechanisms of HIV-1 CA assembly and host factor interactions, HIV-2 CA assembly remains poorly understood. By templating the assembly of HIV-2 CA on functionalized liposomes, we report high-resolution structures of the HIV-2 CA lattice, including both CA hexamers and pentamers, alone and with peptides of host phenylalanine-glycine (FG)-motif proteins Nup153 and CPSF6. While the overall fold and mode of FG-peptide binding is conserved with HIV-1, this study reveals distinctive features of the HIV-2 CA lattice, including differing structural character at regions of host factor interactions and divergence in the mechanism of formation of CA hexamers and pentamers. This study extends our understanding of HIV capsids and highlights an approach facilitating the study of lentiviral capsid biology.

### In brief

Cook and Freniere et al. determine and analyze structures of the mature assembly of HIV-2 capsid protein. While structurally similar to HIV-1, HIV-2 CA capsomeres form via a distinct mechanism independent of HIV-1 determinants. Despite variation in contact residues, the binding of FG-motif proteins appears conserved.

### Graphical Abstract

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

\*Correspondence: [yong.xiong@yale.edu](mailto:yong.xiong@yale.edu).

<sup>2</sup>These authors contributed equally

<sup>3</sup>Lead contact

#### AUTHOR CONTRIBUTIONS


M.C., C.F., and Y.X. conceived this project and designed the study; C.F. prepared the functionalized liposomes, expressed and purified the HIV-1 protein, assembled SUV-templated HIV-1 CLPs, prepared EM samples, collected cryo-EM data, and performed cryo-EM reconstruction; M.C. expressed and purified the HIV-2 protein; M.C. assembled CLPs and prepared samples with discussion from C.F.; M.C. and F.L. performed assembly and co-sedimentation assays; M.C. performed negative-stain EM imaging; C.F. and C.W. performed cryo-EM data collection; C.F. and X.Y. performed cryo-EM reconstruction; M.C. performed model building with discussion from C.W., C.F., and Y.X.; M.C., C.F., and Y.X. analyzed the data; M.C., C.F., and F.L. wrote the paper; M.C. and C.F. created the visualizations; and M.C., C.F., and Y.X. edited the paper. All of the authors discussed the results and commented on the manuscript.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

#### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2025.115245>.



## INTRODUCTION

Human immunodeficiency virus type 2 (HIV-2) was first identified in West Africa in 1986 among patients exhibiting AIDS symptoms.<sup>1,2</sup> The virus arose from a zoonotic spillover event separate from HIV-1, specifically deriving from a simian immunodeficiency virus infecting sooty mangabeys (SIV<sub>smm</sub>).<sup>3,4</sup> While capable of progressing to AIDS when untreated, HIV-2 features slower average disease progression and lower viral loads compared to HIV-1.<sup>5–7</sup>

During HIV-1 or HIV-2 infection, the capsid is a necessary component that protects the viral genome and recruits host factors while trafficking to the nucleus.<sup>8–10</sup> Acting as the shell of the virus core, the capsid is a major nexus for interactions with a large array of both pro-viral and restrictive host factors.<sup>11,12</sup> The vital role of the capsid and the many proteins targeting it apply significant selective pressure on the capsid protein (CA), and it is therefore broadly genetically fragile.<sup>13,14</sup> Consequently, CA sequences are relatively well conserved among lentiviruses.<sup>15</sup>

Following the CA conservation, many host factors that interact with the capsid are conserved between lentiviruses. One class of interacting factors in common is phenylalanine-glycine (FG)-motif proteins such as Nup153 and CPSF6.<sup>8,11,12</sup> Both HIV-1 and HIV-2 experience reduced infectivity and integration site specificity upon Nup153 or CPSF6 depletion.<sup>16–24</sup> These interactions are mediated by the capsid, and mutations to largely conserved CA residues can abrogate the interactions.<sup>17–20,25–28</sup> RANBP2/Nup358 also bears an FG region

but appears to primarily engage in capsid interactions via its cyclophilin homology (CycH) domain,<sup>16,23,29–32</sup> which is structurally similar to cyclophilin A (CypA), which HIV-1 co-opts for an array of functions critical for the viral life cycle, including TRIM evasion.<sup>31,33–40</sup> CypA and CycH bind to a proline-rich loop in CA that is more variable in sequence than other regions.<sup>41</sup> While HIV-2 can also be bound by CypA, the interaction is significantly weaker and has only a small effect on HIV-2 infection, marking it as one significant variation in host factor recruitment.<sup>42</sup> Among restrictive host factors, recognition of HIV-1 versus HIV-2 can also be distinct.<sup>43–45</sup> For example, human antiviral proteins TRIM5 $\alpha$ <sup>31,45–51</sup> and NONO<sup>52</sup> are potent restrictors of HIV-2 but have more limited effects on HIV-1. These differences have been primarily attributed to differences in capsid binding.<sup>52,53</sup>

The capsid is comprised of approximately ~1,600 copies of CA molecules, which oligomerize into ~250 hexamers and 12 pentamers (capsomeres) to form the distinct fullerene cone.<sup>11,54–57</sup> As the capsid is indispensable for successful infection, its pleomorphism is a key feature of HIV biology.<sup>36,55,58–65</sup> Understanding of the mechanisms of the accommodation of HIV-1 CA hexamers and pentamers in the capsid has recently advanced considerably alongside the ability to resolve structures of HIV-1 capsomeres in capsid-like lattices. It has been reported that the <sub>58</sub>TVGG<sub>61</sub> loop of HIV-1 CA acts as a molecular “switch” between the hexamer and pentamer, promoting the remodeling of the hydrophobic core, gating of a host factor binding pocket, and adjusting inter-chain contacts among CA molecules.<sup>64,65</sup>

Electron microscopy (EM) imaging has demonstrated that mature HIV-2 capsids share consistent morphology with HIV-1.<sup>66–68</sup> Nuclear magnetic resonance (NMR) has been used effectively to determine the structures of other elements of the HIV-2 structural polyprotein precursor, namely the matrix and nucleocapsid domains.<sup>69–71</sup> The structure of the immature HIV-2 capsid lattice constructed from cryo-EM has recently been reported.<sup>72</sup> While high-resolution crystal structures of the individual N-terminal domain (NTD)<sup>42</sup> and C-terminal domain (CTD)<sup>72</sup> of HIV-2 CA have been solved, the current methods are inadequate for probing the high-resolution details of mature HIV-2 CA lattice assembly and its interactions with host factors, as the formation of the mature HIV-2 CA lattice has proven to be more challenging compared to that of HIV-1 CA.<sup>73</sup> As such, the structural details underscoring the biologic role of the assembled mature HIV-2 capsid lattice remain poorly characterized. Given the recent progress in developing approaches to understand HIV-1 CA,<sup>74,75</sup> HIV-2 CA affords an opportunity to illuminate broader lentiviral capsid biology and potentially provide future directions for pharmacological intervention.

In this study, we leveraged the approach of templating the HIV CA lattice assembly on liposomes,<sup>75</sup> together with stabilization by the small-molecule host factor inositol hexakisphosphate (IP6),<sup>75–79</sup> to produce regular HIV-2 CA lattices. We report the first high-resolution structures of HIV-2 CA capsomeres in their native mature lattice using single-particle cryo-EM. While the structures are broadly conserved, the mechanisms of hexamer/pentamer switching appear to differ between HIV-2 and HIV-1, suggesting the divergent evolution of these lentiviral capsid systems. In addition, we highlight that this system can be used to study host factor-CA lattice interactions via structural resolution of complexes of HIV-2 CA assemblies with peptides of FG-motif proteins. In summary,

we provide new insights into the mechanisms of HIV-2 capsid assembly and host factor targeting.

## RESULTS

### A capsid-like lattice of HIV-2 CA can be assembled via liposome templating

The understanding of HIV-1 capsid biology has expanded significantly alongside an array of tools and approaches for reproducing the mature CA lattice with *in vitro* assemblies.<sup>54,55,74–76,80–83</sup> While functionally and structurally conserved, HIV-2 CA is distinct, with differing effects on infectivity and host factor interactions.<sup>5,31,43–52</sup> As no effective approaches for determining atomic-level structures of the HIV-2 capsid exist, we sought to identify a platform for the assembly of HIV-2 CA into capsid-like particles (CLPs) and resolve high-resolution structures of the mature CA lattice via cryo-EM. Recent work demonstrated the efficient assembly of HIV-1 CLPs via protein templating on liposomes decorated with Ni-NTA (nickel-nitrilotriacetic acid) head groups.<sup>75</sup> We adopted this approach for HIV-2 CA assemblies.

Templating is achieved by the association of His-tagged CA molecules with the Ni-NTA-modified lipid head groups in the liposome; we therefore introduced a C-terminal His tag to HIV-2 GL-AN<sup>84</sup> CA with an intervening Gly-Ser-Ser linker. As such, the numbering used in this work is based on the HIV-2 GL-AN sequence, which is offset by +1 from the common HIV-2 ROD<sup>2</sup> sequence after residue 8. We purified the protein to homogeneity. Incubation of the purified protein with small unilamellar vesicles (SUVs; Figures S1A and S1B) and IP6 resulted in the formation of CLPs marked by increased turbidity and the ability to pellet the CLPs via centrifugation. Imaging of the CLPs by negative-stain EM revealed liposomes decorated with a repeating lattice similar to what had been observed with HIV-1 CLPs<sup>75</sup> (Figure S1C). Pelleted CLPs could be resuspended in a range of buffer pH values (6.0–8.5) and salt concentrations (0–1 M NaCl) and maintain assembly, though with decreasing efficiency at lower or higher pH or high salt (Figures S1D–S1G). HIV-2 CA assembled poorly with only dNTPs or without any polyanions, similar to HIV-1 (Figures S1H and S1I). CA assemblies were stable for several days on ice or at 4°C.

### High-resolution lattice structures of templated HIV-2 CLP assemblies by cryo-EM

Liposome-templated HIV-2 CLP assemblies were well behaved as cryo-EM samples (Figure 1A), allowing for the determination of high-resolution structures (Figure 1; Table S1). A cryo-EM map of the mature-like HIV-2 CA hexamer with C6 symmetry was resolved to 3.26 Å resolution (Figures 1B and S2). In the initial stages of map classification and reconstruction, a subset of pentamers were observed adjacent to the central hexamer (Figure S2). Pentamer-containing particles were re-processed with C5 symmetry to reconstruct an HIV-2 CA pentamer map to 2.97 Å resolution (Figures 1C and S2). In the final stages of processing the pentamer maps, a small portion of pentamer-containing particles were identified in assemblies with the appearance of T = 1 pentamer icosahedra<sup>64</sup> (Figure 1A). These particles were re-picked and processed using icosahedral symmetry, yielding a 1.98 Å resolution map of the HIV-2 pentamer icosahedra (Figures 1D, 1E, and S3). The icosahedral pentamer was nearly identical to the pentamer from the CLPs with a model root-mean-

square deviation (RMSD) of  $\sim 0.7$  Å. Consistent with the high resolution, excellent density is observed, and we can confidently build an atomic model of the CA molecule in the assembly (Figure 1F).

Globally, both hexamer and pentamer maps were similar to those of HIV-1 CA assemblies.<sup>57,64,65,75</sup> We observed density for IP6 in the central pores of both HIV-2 CA hexamers and pentamers, with clear density for R18 side chains (Figures 2A and 2B). Density for a lower IP6 was also clear, though in the hexamer, it was less well resolved than the upper density, and likewise, K25 side-chain density was more modest. As had been posited for the HIV-2 capsid lattice, the central pore appeared most similar to the open N-terminal  $\beta$ -hairpin conformation of the HIV-1 CA hexamer central pore,<sup>45</sup> despite HIV-1 CA occupying the closed conformation in the pH range used for HIV-2 assembly (between pH 7.5 and 8.0)<sup>85</sup> (Figure S4A). For both pentamers and hexamers, one of the most striking features of the map when compared with HIV-1 was the stronger density of the CypA-binding loop (Figures 2C, S4B, and S5; Table S1).

### The HIV-2 CA lattice exhibits distinctions from corresponding HIV-1 structures

Atomic models of HIV-2 CA could be confidently built into all maps and included all residues except those C-terminal to helix 11 (Table S2; Figure S4C). The hexamer NTD aligned closely with the previously determined crystal structure of the HIV-2 CA NTD (PDB: 2WLV)<sup>42</sup> ( $\sim 0.9$  Å RMSD; Figure 2C). This included structural conservation at the rare E97D mutation of GL-AN, which retains its formation of a salt bridge with R119 (residues E96 and R118, respectively, in HIV-2 ROD), hypothesized to stabilize the CypA-binding loop (Figure 2C, top left).<sup>45</sup> Differences between the two structures largely occurred at protomer interfaces, either with adjacent chains or with the CTD (Figure 2C). Likewise, the hexamer CTD and previous HIV-2 CA CTD crystal structure (PDB: 7TV2)<sup>72</sup> aligned closely ( $\sim 0.9$  Å RMSD) (Figure 2C). However, the loop between helices 8 and 9 is shifted in the hexamer structure to allow Q176 in the CTD to contact residues Q139 and R143 in the NTD (Figure 2C, bottom left). Furthermore, the previously described position of helix 12 in the CTD would clash with adjacent chains in our structure (Figures S4D–S4G).

The HIV-2 models reported here aligned closely with previously determined HIV-1 structures when comparing both hexamers<sup>61</sup> ( $\sim 1.7$  Å RMSD) and pentamers<sup>65</sup> ( $\sim 1.1$  Å RMSD; Figure S6A). As such, HIV-2 CA protomers also adopt significant conformational differences to accommodate forming both the pentamer and hexamer. However, considerable details underlying this structural plasticity differ. These differences also compound into identifiable changes in CA assemblies, with the central pore diameters expanding by  $\sim 2.7$  Å in the hexamer<sup>61</sup> and  $\sim 1.6$  Å in the pentamer<sup>65</sup> compared to HIV-1 at the Ca position of the R18 ring (Figure 3A). The pore diameter at the R18 ring in HIV-1 is approximately the same whether in the open or closed  $\beta$ -hairpin conformation,<sup>85</sup> so the HIV-2 capsomere being locked in the open conformation does not appear to explain this difference. Comparing regions of the capsomeres, the arrangement of NTD cores of HIV-2 is generally wider. In both viruses, CA NTD-NTD inter-protomer contacts are mediated by the N-terminal three-helix bundle, and most side-chain interactions are conserved or similar.<sup>83</sup> However, while in HIV-1, the shift to the pentameric conformation excludes helix 3 from inter-chain



contacts,<sup>64,65</sup> helix 3 of HIV-2 CA remains engaged at the assembly interface with helix 2 from the adjacent chain through residues well conserved within HIV-2 but that are divergent compared to HIV-1 (Figures 3B, S6B, and S6C). Specifically, we observed an exchange of polar contacts, as the hydrogen bonding potential of helix 2 residues Q41 and E45 is met by either Y50 and Q54 in the hexameric conformation or N57 and Q54 in the pentamer, allowing a change in register as helix 3 slides along helix 2.

While the <sub>58</sub>TVGG<sub>61</sub> loop of HIV-1 has been described as a molecular switch between the pentamer and hexamer,<sup>64,65</sup> the <sub>58</sub>CVGD<sub>61</sub> loop of HIV-2 does not demonstrate such a significant structural shift, though it is still structurally distinct between the two conformations (Figure 3C). The <sub>58</sub>CVGD<sub>61</sub> loops of both conformations in HIV-2 are more similar to the pentameric conformation of HIV-1,<sup>65</sup> though no <sub>310</sub> helix is formed. Instead, D61 is engaged in distinct contacts with the CTD from the adjacent chain. Similar to the alternating NTD contacts, this interface permits a shift in the helical register to accommodate either the hexameric or pentameric form (Figure 3D). In the hexamer, D61 and Q63 of one CA NTD form interactions with residues of the adjacent CA CTD, K170 and R173 (Figures 3E, S6B, and S6D). Upon shifting to the pentamer, D61 replaces Q63 to ionically interact with adjacent CTD residue R173, while K31 of the NTD contacts the adjacent D166 (Figures 3F, S6B, and S6E). These contacts are unique compared to HIV-1.<sup>61,65</sup> Furthermore, we do not observe notable remodeling of the hydrophobic core of the NTD between the hexamer and pentamer, and the M39G mutation in HIV-2 precludes the ability of that residue to contribute to shifting knob-in-hole packing against adjacent chain helices, as had been described for HIV-1.<sup>64</sup> In addition, we did not observe that residue M66 exhibits significant structural alterations between the oligomer states, different from what had been described as a gating mechanism for the hexamer-pentamer transition in HIV-1<sup>64,65</sup> (Figure S6F).

### Atomic details of FG-peptide binding to HIV-2 CA assemblies

With reproducible assemblies of HIV-2 CA amenable to a structural study, we sought to resolve the binding of FG peptides derived from Nup153 and CPSF6 to identify differences in interactions compared to the HIV-1 capsid.<sup>18,21,25–27,65,86</sup> Additionally, since the conformational change of residue M66 contributes to exclude the binding of FG peptides to HIV-1 CA pentamers, we were curious whether the FG peptides could bind to the HIV-2 CA pentamer that does not have steric occlusion by M66 rearrangement.

Binding of the Nup153 peptide (residues 1411–1425/1464–1475)<sup>26</sup> was detected by co-sedimentation assays pelleting the liposome-templated CA assembly (Figure S7A). CA-SUV assemblies mixed with either peptide remained well behaved under both negative-stain EM and cryo-EM imaging conditions (Figure S9B). In addition, the induced assembly of apparent HIV-2 CA nanotubes with the introduction of the Nup153 peptide was observed (Figure S7B). Following cryo-EM analysis, high-resolution structures of the HIV-2 CA hexamer (2.98 Å resolution) and pentamer (2.99 Å resolution) in the presence of the Nup153 peptide and the hexamer (3.16 Å resolution) and pentamer (2.82 Å resolution) in the presence of the CPSF6 peptide (residues 313–327)<sup>86</sup> were determined (Figures 4 and S8).

Nup153 FG-peptide density was readily observed in the FG pockets of HIV-2 CA hexamers (Figure 4A) but not pentamers (Figures S7C and S7D). The density was strongest inside the FG pocket and extended to contact the CTD of the adjacent CA chain. An atomic model of 8 residues of the Nup153 peptide could be confidently built (Figure 4C; Table S2). Consistent with the high conservation of FG pocket residues between HIV-1 and -2, the model of the Nup153 peptide in HIV-2 aligned closely with the known structure of the Nup153 peptide in the HIV-1 CA hexamer<sup>65</sup> (~0.5 Å RMSD). This is true in spite of divergent residues between the two viruses, which may have been expected to alter binding. In HIV-1 CA, the K70R mutation has been shown to lower the affinity of interaction with FG-pocket binding factors, including Nup153,<sup>19</sup> but the well-conserved R70 residue of HIV-2 CA does not appear to affect binding. Similarly, residues along the adjacent CA NTD present more polar character near the HIV-2 CA FG pocket, which may have otherwise been expected to interact poorly with the first Phe of the Nup153 FxFG peptide (Figure 4C). Consistently, the PRODIGY web server<sup>87–89</sup> predicted similar binding energies for the Nup153 peptide to both CA assemblies: -7.2 kcal/mol to HIV-1 CA and -7.4 kcal/mol to HIV-2 CA.

Similarly, CPSF6 FG-peptide density was readily observed in the FG pockets of HIV-2 CA hexamers (Figure 4B) but not pentamers (Figures S7C and S7E). This density was nearly as strong as the main-chain CA density and appeared to mainly contact one CA chain. An atomic model of 11 residues of the CPSF6 peptide could be confidently built (Figure 4D; Table S2). The FG segment of the peptide bound similarly to the Nup153 peptide and was overall similar to the structure determined previously of the CPSF6 peptide with the HIV-1 CA hexamer<sup>86</sup> (~0.4 Å RMSD). Interestingly, we observed a clear interaction between two Gln residues of the CPSF6 peptide (Q319 and Q323 of CPSF6) with backbone amide groups of the HIV-2 CA. These residues are also available in HIV-1 CA with similar conformations, but their interactions with the CPSF6 peptide were not observed previously (Figure 4D).<sup>86</sup> Consequently, binding energy prediction by the PRODIGY web server<sup>87–89</sup> predicted tighter binding of the CPSF6 peptide to HIV-2 CA (-9.0 kcal/mol) compared to HIV-1 CA (-5.4 kcal/mol). Despite resolving high-resolution structures of pentamers in the same datasets containing FG-peptide-bound hexamers, no density for either FG peptide was observed to bind to the HIV-2 CA pentamer, like HIV-1, even in the absence of steric hindrance caused by the M66 rearrangement.

## DISCUSSION

The viral capsid is indispensable to lentiviral infection and defines various sites of distinguishing host interactions between HIV-1 and HIV-2.<sup>5,31,43–52</sup> By leveraging an approach that has produced mature CA lattice assembly in HIV-1,<sup>75</sup> we have determined structures of the HIV-2 CA lattice assembly at high resolution containing both hexameric and pentameric conformations. These structures shared significant similarity to previously determined crystal structures of individual HIV-2 CA domains<sup>42,72</sup> and corresponding HIV-1 CA protomers<sup>61,64,65,75</sup> but diverged at inter-domain or inter-protomer interfaces or at locations of genetic divergence with HIV-1. These assemblies offer an accurate and reproducible representation of the mature HIV-2 capsid lattice, providing an efficient tool to study interactions with host factors.

While globally similar to HIV-1, these structures reveal distinctive regions in the HIV-2 CA lattice. The expanded central pore does not appear to affect the coordination of IP6. However, it may have implications on IP6 binding properties at the R18 or K25 ring and, thus, the rate of dNTP diffusion into the enclosed capsid. Additionally, the ordering of the CypA-binding loop, which is not a well-resolved feature in previously determined HIV-1 capsid structures,<sup>56,62,64,65,75</sup> provokes questions about the mechanism underlying differential interactions with an array of host factors, including CypA and RANBP2/Nup358.<sup>31,42,90</sup> Further, we identified diverging mechanisms to stabilize hexamer or pentamer formation. HIV-2 CA assemblies appear to lack the rearrangement of the hydrophobic core reported for HIV-1 capsomeres.<sup>64,65</sup> Indeed, the divergence of M39G in HIV-2 CA may preclude adopting the same mechanism as has been described for HIV-1. Instead, the HIV-2 CA structures exhibit several additional polar contacts between adjacent chains, particularly between NTD helices 2 and 3, which could explain how they modulate forming pentamers and hexamers. This subtle rearrangement suggests that the <sub>58</sub>CVGD<sub>61</sub> loop of HIV-2 functions more gradually than the switch mechanism proposed for HIV-1.<sup>64,65</sup> In accordance with this model, we observe icosahedral pentamer-only particles without kinetically trapping a molecular switch in a particular state by mutation.<sup>64</sup>

With reliable atomic models of both HIV-1 and HIV-2 capsomeres revealing details of complex formation, we can better analyze the evolutionary space of primate lentiviruses. When focusing on residues at the interfaces of the assemblies, two trends quickly become apparent. First, M39 is well conserved among primate lentiviruses, with the M39G mutation appearing only in the monophyletic grouping of closely related HIV-2 and SIV<sub>smm</sub>. This group also exhibits the mutations V/A26L and S/T41Q nearby in space (Figure 5B). L26 appears to partially compensate for the conversion of M39 to glycine in maintaining the hydrophobic interface and would otherwise clash with M39 if both were present (Figure 5C). This is consistent with the assembly and maturation issues exhibited by HIV-2 G39M (G38M in HIV-2 ROD) revertant mutants.<sup>91</sup> Q41 permits hydrogen bonding with residues on helix 3. A hydrogen-bonding partner of Q41, Q54, appears in a slightly broader monophyletic grouping, adding the SIV<sub>rcm</sub> and SIV<sub>tan</sub> branches. It is possible that Q54 arose first and was followed by Q41 to interact with and stabilize helix 2–3 interactions, permitting the M39G and V26L mutations.

Sequence elements of the pentamer switch loop <sub>58</sub>TVGG<sub>61</sub> of HIV-1 CA appear uniquely in the HIV-1/SIV<sub>cpz</sub>/SIV<sub>gor</sub> monophyletic group. The HIV-2-related group, as well as the more ancestrally related SIV<sub>mnd</sub>, exhibit well-conserved D/E61, which we identified as forming ionic interactions with K170/R173 in HIV-2 assemblies. It is unclear how this potential interaction would affect the switch remodeling of the <sub>58</sub>TVGG<sub>61</sub> loop, but D/E61G is particular to the HIV-1-related group (Figure 5B). Further, this HIV-1-related grouping also appears to lose K31 as a potential CTD contact in the pentamer but gains P/A179Q to hydrogen bond with Q63 in the adjacent chain, potentially as a trade-off to accommodate other structural changes. Taken altogether, these series of mutations provide clues for different scenarios regarding the evolution of the mechanisms of achieving CA pleomorphism.



With high-resolution HIV-2 CA lattice structures, one can identify surface residues with conserved changes of chemical character between HIV-1 and HIV-2, which lack clear structural reasons for divergence. This may imply that elements of this set potentially contribute to differential host factor binding. Despite these and other differences, the mode of FG-peptide binding for those we tested appeared largely conserved. The mechanism of the K70R mutation destabilizing HIV-1 CA-Nup153 interactions also remains unclear from our structures.<sup>19</sup> Furthermore, despite the lack of M66 gating in HIV-2, we did not observe density for either the CPSF6 or Nup153 peptide in the FG pocket of CA pentamers, indicating that another mechanism is responsible for the reduced binding to HIV-2. Future studies leveraging the efficient *in vitro* assembly system and functional experiments will answer more questions regarding HIV-2/HIV-1 capsid lattice structure formation and host factor binding, presenting many new opportunities to better understand the biology and evolution of these viruses.

### Limitations of the study

While we believe there is a strong basis for confidence that the structures described here are true reflections of the HIV-2 capsid, the structures reported here are not derived from native HIV-2 cores. As such, there remains the possibility that some details differ between our reconstituted system and the native CA lattice. One distinguishing feature of the liposome-templated HIV-2 CLPs is their smaller size and, therefore, higher curvature and greater extent of pentamer incorporation, assuming complete lattice enclosure. This could contribute to an overrepresentation of inter-capsomere curvature in this study. That being said, the capsomere maps we report do match closely in curvature with comparable HIV-1 CA lattice maps resolved from non-templated assemblies.<sup>64,65,75</sup> Furthermore, while we identify that HIV-2 appears to lack the means to stabilize hexamer/pentamer formation as has been described for HIV-1 and offers a potential alternative mechanism derived from our structural and evolutionary analyses, we lack orthogonal approaches to conclusively prove that the mechanism underlying HIV-2 CA pleomorphism is as we suggest it to be.

This study uses the CA sequence of the GL-AN strain of HIV-2. While commonly used in laboratory settings, some residues are divergent from a consensus sequence of HIV-2 genomes from the Los Alamos National Laboratory database. The majority of the variation identified was present in the N-terminal  $\beta$ -hairpin. The variations elsewhere were largely similar in chemical character. As such, we concluded the differences were minor but cannot rule out that other HIV-2 CA structures may appear distinct in some regions.

## RESOURCE AVAILABILITY

### Lead contact

Further information and requests for plasmids, resources, and reagents should be directed to and will be fulfilled by the lead contact, Dr. Yong Xiong (yong.xiong@yale.edu).

## Materials availability

The plasmid pET11a GL-AN HIV-2 CA-GSSHHHHHH was produced for this study and is available upon request. The plasmid pET28a NL4–3 HIV-1 CA-6xHis is also available upon request.

## Data and code availability

- EM reconstruction maps reported here have been deposited with the Electron Microscopy Data Bank and have been made available by the date of publication. The accession codes are as follows: HIV-2 CA icosahedron (EMD: EMD-45676), HIV-2 CA hexamer (EMD: EMD-45758), HIV-2 CA pentamer (EMD: EMD-45759), HIV-2 CA hexamer with Nup153 peptide (EMD: EMD-45760), HIV-2 CA hexamer with CPSF6 peptide (EMD: EMD-45761), HIV-2 CA pentamer from the Nup153 dataset (EMD: EMD-45762), HIV-2 CA pentamer from the CPSF6 dataset (EMD: EMD-45763), and HIV-1 CA pentamer (EMD: EMD-47600).
- Atomic models reported here have been deposited with the Protein Data Bank and have been made available by the date of publication. The accession codes are as follows: HIV-2 CA icosahedron (PDB: 9CLJ), HIV-2 CA hexamer (PDB: 9CNS), HIV-2 CA pentamer (PDB: 9CNT), HIV-2 CA hexamer with Nup153 peptide (PDB: 9CNU), and HIV-2 CA hexamer with CPSF6 peptide (PDB: 9CNV).
- The nucleotide sequence of the reading frame of the pET11a GL-AN HIV-2 CA-GSSHHHHHH expression plasmid has been deposited with GenBank and is available with accession number GenBank: [PQ189021](#).
- This paper does not report original code.
- Any additional information required to reanalyze the data presented in this paper is available from the lead contact upon request.

## STAR★METHODS

### EXPERIMENTAL MODEL AND SUBJECT PARTICIPANT DETAILS

**Bacterial expression**—The BL21(DE3) strain of *E. coli* was used for recombinant expression of viral protein constructs. Cells were grown to OD<sub>600</sub> ~0.8 in Terrific broth before induction with 500 μM isopropyl β-*d*-1 thiogalactopyranoside at 18°C for 16 h and then collected by centrifugation. Pellets were either used immediately for protein purification or flash frozen and stored at –80°C.

### METHOD DETAILS

**Protein expression and purification**—A hexahistidine tag with Gly-Ser-Ser linker was cloned onto the C terminus of GL-AN HIV-2 CA in pET11a vector. GL-AN HIV-2 CA-GSSHHHHHH was expressed in BL21(DE3) competent cells. Expression cells were resuspended in lysis buffer (50 mM Tris·HCl, pH 8.0 at 4°C; 500 mM NaCl; 0.2 mM tris(2-carboxyethyl)phosphine (TCEP); 1 × Halt protease inhibitor cocktail) and lysed

in a microfluidizer. The lysate was clarified via centrifugation before bulk protein was precipitated from the supernatant with 35% ammonium sulfate (stirring at 4°C for 1 h). Precipitated protein was collected by centrifugation and then resuspended in NiNTA Buffer A (50 mM Tris-HCl, pH 8.0; 350 mM NaCl; 20 mM imidazole; 0.2 mM TCEP). The resuspended protein was clarified by centrifugation and then loaded onto a 5mL hand-packed column of NiNTA agarose resin (Qiagen). Protein was eluted with NiNTA Buffer B (50 mM Tris-HCl, pH 8.0; 350 mM NaCl; 300 mM imidazole; 0.2 mM TCEP) in a stepwise fashion. The eluted peak was then dialyzed against cation exchange Buffer A (25 mM Na-HEPES, pH 6.9; 50 mM NaCl; 0.2 mM TCEP) overnight (stirring at 4°C). The dialyzed protein was clarified by centrifugation and loaded onto a 5 mL HiTrap SP HP column (Cytiva) for cation exchange chromatography. The protein began eluting around 25% of the way through a 50 mM to 1 M NaCl gradient. Protein was concentrated to 1 mM concentration and snap frozen with final buffer containing 300 mM NaCl. The C-terminally His-tagged HIV-1 CA protein was purified in the same manner detailed above.

**Liposome preparation**—The preparation scheme was adapted from Highland et al., 2023.<sup>75</sup> Chloroform stock solutions of 1,2-dioleoyl-*sn*-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DGS-NiNTA) and 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC) were purchased from Avanti Polar Lipids. Cholesterol was purchased from Thermo Scientific Chemicals and resuspended at 5 mg/mL in chloroform. Lipids were mixed at an 85:10:5 DOPC:DGS-NiNTA:Cholesterol ratio using a volumetric flask so that the final composition of the lipid mixture is roughly 95% DOPC, 2% DGS-NiNTA, and 3% cholesterol. The lipid mixture was transferred to a round bottom flask and dried by rotary evaporation for 5 h. The resulting “lipid cake” was resuspended in aqueous buffer (25mM HEPES pH 7.4, 150mM KCl) to a final concentration of 13 mM by gentle agitation on a rotovap. The resuspended “lipid cake” was allowed to hydrate overnight at room temperature. Large unilamellar vesicles (LUVs) were prepared by extruding the hydrated lipid cake through a 100 nm polycarbonate membrane 100 times at 37°C. Small unilamellar vesicles (SUVs) were prepared by sonication with a nanoprobe tip at 50% amplitude for 15 min of processing time (10 s pulse, 50 s off). Lipid preparations were verified by negative stain EM before use in assembly assays (Figures S1A and S1B).

**CA assembly by liposome templating and cosedimentation**—Capsid like particles (CLPs) were assembled by mixing the following components to the given final concentrations: 2.5 mM IP6, 3.7 mM SUV or LUV lipids, and 250 μM GL-AN HIV-2 CA-GSS-6xHis. A 6x buffer (150 mM Tris-HCl, pH 8.0 (RT); 1800 mM NaCl) was also added, diluting to 1x and producing a final buffer make-up of approximately 25 mM Tris-HCl, pH 8.0; 10 mM HEPES, pH 7.3; 25 mM KCl; 345 mM NaCl. The final buffer pH was determined by pH strip at room temperature to be between 7.5 and 8.0. The particles were assembled during a 15 min incubation at 37°C and allowed to recover for 5 min at room temperature. HIV-1 CLPs were assembled under the same conditions using a concentration of 190 μM HIV-1 CA. To study the binding of Nup153 peptide or CPSF6 peptide and HIV-2 CLPs, the FG-peptide was added to the already-assembled CLPs following recovery. The FG-peptide-CLP complex was then allowed to form during a 30 min incubation at room temperature.

To test binding via cosedimentation, samples were pelleted down by centrifugation at 16k ref for 20 m using a room temperature tabletop microcentrifuge. The supernatant was then drawn off, which was typically around the original sample volume. The pellet was washed with an equivalent volume of desired buffer before centrifuging again at 16k ref for 5 m. Wash buffer was removed and the pellet was resuspended in equivalent buffer volume for subsequent analysis by SDS-PAGE or EM imaging.

**Negative stain EM of liposomes and CLPs**—3.5  $\mu$ L of liposome sample was applied to a glow-discharged negative stain EM grid (EMS, carbon on 300-mesh copper) for 1 min. The grid was washed 1X with buffer (25mM HEPES pH 7.4, 150 mM KCl) then stained in 2% uranyl acetate for 1 min and blotted with filter paper. For CLPs, a 3.5  $\mu$ L sample diluted 1:4 in buffer was deposited onto glow-discharged (25 mA for 30 s) 400 mesh carbon-coated copper grids (Electron Microscopy Services) for 1 min before blotting. Grids were stained with 2% uranyl acetate solution (Electron Microscopy Services) for 90 s before blotting. Imaging was conducted on a 120 kV Talos L120C TEM with CETA CMOS camera.

**Cryo-EM sample preparation**—A volume of 3.5  $\mu$ L of CLPs was deposited onto glow-discharged (15 mA, 45 s) Quantifoil R 2/1 200 mesh copper grids. Sample was dual-side blotted for 5.5–7.5 s by a Vitrobot (ThermoFisher) with chamber at 100% humidity and then plunge-frozen in liquid ethane.

**Cryo-EM data collection and processing**—Cryo-EM data were collected at Brookhaven National Laboratory (BNL) and Yale University cryo-EM facilities. In each case, movies were collected using a 300 kV Titan Krios (ThermoFisher) equipped with an energy filter and a K3 direct detector (Gatan). Movies were collected using EPU (ThermoFisher) (BNL) or SerialEM<sup>95</sup> (Yale) at a physical pixel size of 1.068 Å (Yale) or 1.07 Å (BNL) in super-resolution mode with a total dose of 50 electrons per Å<sup>2</sup> and a target defocus of –0.8 to –2.0  $\mu$ m.

Image processing was performed using CryoSPARC.<sup>96–98</sup> For the HIV-2-SUV dataset, 6,037 movies were subjected to patch motion correction (bin2, pixel size 1.068 Å) and CTF estimation. Initial manual picking of 1,213 particles followed by 2D classification yielded usable templates for template-based particle picking. Separate template picking jobs were performed to pick “top” and “side” views of the capsid lattice. After manual inspection, duplicate particles were removed and the remaining 13,209,858 particles were extracted using a box size of 104 pixels (bin4, pixel size 4.272 Å). Extracted particles were subjected to several rounds of 2D classification and selection. The remaining 3,065,617 particles were subjected to C1 homogeneous refinement with EMD-3465<sup>62</sup> low-pass filtered to 40 Å. Subsequent heterogeneous refinement of the 3,065,617 particles using 4 identical reference volumes (EMD-3465<sup>62</sup> lowpass filtered to 40 Å) yielded two hepta-hexamer classes (total 1,572,733 particles), one class containing pentamer (1,030,843 particles), and a junk class.

Pentamer containing particles were used for a C5 ab-initio reconstruction which resulted in a map that features a central pentamer adjacent to five hexamers. At this point, particles were re-extracted in box size of 416 pixels (pixel size 1.068 Å) without binning. These particles were used for homogeneous refinement, 3D classification, non-uniform refinement,

and several rounds of iterative local refinement paired with per-particle CTF refinements (global and local CTF estimations), ultimately yielding a 2.97 Å map (346,785 particles).

Likewise, hexamer containing particles were used for a C6 ab-initio reconstruction, which resulted in a map that features a central hexamer surrounded by six others. At this point, particles were re-extracted in box size 416 (pixel size 1.068 Å) without binning. These particles were used for homogeneous refinement, 3D classification, non-uniform refinement,<sup>99</sup> and several rounds of iterative local refinement paired with per-particle CTF refinements (global and local CTF estimations), ultimately yielding a 3.26 Å resolution map (603,473 particles).

For the HIV-2-Nup153 peptide dataset, 3,732 movies were collected and motion correction, CTF estimation, and initial particle picking were performed as previously described. After template picking, 11,931,864 particles were subjected to multiple rounds of heterogeneous refinement using 3 identical volumes (EMD-3465<sup>62</sup> lowpass filtered to 40 Å) and 2 junk volumes (EMD-3465 lowpass filtered to 100 Å). After five rounds of heterogeneous refinement the total percentage of particles sorted to junk dropped below 1% and the refinement was considered to have converged. Pentamer-containing particles were aligned to the apo HIV-2 pentamer volume using homogeneous refinement and re-extracted in box size 180 (pixel size 1.068 Å). These particles were used for homogeneous refinement, non-uniform refinement, and several rounds of iterative local refinement paired with per-particle CTF refinements (global and local CTF estimations), ultimately yielding a 2.99 Å resolution map (1,259,201 particles). A parallel procedure for the hexamer-containing particles, aligning to the apo HIV-2 hexamer volume, yielded a 2.98 Å resolution map (1,494,376 particles).

For the HIV-2-CPSF6 peptide dataset, 5,506 movies were collected and motion correction, CTF estimation, and initial particle picking were performed as previously described. After template picking, 23,033,474 particles were subjected to multiple rounds of heterogeneous refinement as described above. Similarly, subsequent parallel processing of pentamer-containing and hexamer-containing particles yielded a 2.82 Å resolution pentamer map (1,906,465 particles) and a 3.16 Å resolution hexamer map (2,537,344 particles).

The HIV-1 SUV dataset was collected at Yale University on a 200 kV Glacios equipped with a K3 direct detector (Gatan). Movies were collected using SerialEM<sup>95</sup> at a physical pixel size of 0.868 Å in super-resolution mode with a total dose of 50 electrons per Å<sup>2</sup> and a target defocus of -0.8 to -2.0 μm.

For the HIV-1 SUV dataset, 3,611 movies were collected and motion correction, CTF estimation, and initial particle picking were performed as previously described. After template picking, 7,600,275 particles were subjected to multiple rounds of heterogeneous refinement as described above (performed in bin4, pixel size 3.472 Å). Pentamer containing particles were re-extracted (pixel size 0.868 Å) used for homogeneous refinement, non-uniform refinement, and several rounds of iterative local refinement paired with per-particle CTF refinements (global and local CTF estimations), ultimately resulting in a 3.07 Å resolution pentamer map (745,724 particles).



Pentamer icosahedrons were observed in all HIV-2-SUV samples at a lower abundance. As the HIV-2-CPSF6 sample had the highest particle concentration, we focused our analysis on this dataset. For the pentamer icosahedrons, manual picking of 314 particles yielded clear 2D classes, which were subsequently used for template picking. After manual inspection, 690,629 particle picks were extracted in a box of 102 pixels (bin 4, pixel size 4.272 Å) and subjected to several rounds of 2D classification to remove non-icosahedral lattice particles. 75,595 final selected particles were subjected to ab-initio reconstruction with icosahedral symmetry imposed. The resulting maps featured a micelle coated in 12 pentamers.

Subsequently, the particles were re-extracted in box 384 (pixel size 1.068 Å) with no binning and subjected to homogeneous refinement, non-uniform refinement,<sup>99</sup> and several rounds of iterative local refinement paired with per-particle CTF refinement (global and local CTF estimation), ultimately yielding a 2.18 Å resolution map (74,821 particles). At this point, the particles were subjected to reference-based motion correction<sup>97,100</sup> (super-resolution pixel size 0.712 Å) followed by non-uniform refinement with CTF fitting (tetrafoil, spherical aberration, anisotropic mag),<sup>99</sup> defocus estimation and positive curvature EWS correction yielding a 1.98 Å resolution map (74,821 particles).

**Atomic model building and refinement**—An initial model was prepared in Coot<sup>101,102</sup> by docking the cryo-EM structure of pentameric WT HIV-1 CA from IP6-stabilized CLPs (PDB: 8CKW)<sup>65</sup> into the pentamer-centered cryo-EM map of HIV-2 CA templated on SUV. Coot was then used to manually rebuild the structure to match the density. Iterative rounds of Phenix<sup>103</sup> Real Space Refinements and manual adjustments in Coot were then performed until model quality was evaluated as acceptable. This model was then used as a reference in the icosahedral pentamer cryo-EM map and rebuilt and refined as above. As the icosahedral pentamer model was derived from a higher resolution map, it was then used as initial reference for all subsequent models, including hexamers after adjusting the relative orientation between CA NTD and CTD, which were also refined as above. IP6 models were initially placed using the conformation and orientation from a starting model of the HIV-1 CA assembly structure (PDB 6BHT).<sup>76</sup> The model was further refined using ligand restraints derived from the eLBOW program in Phenix<sup>103</sup> with all chains of the capsomere modeled in by symmetry. All copies of symmetry-related IP6 molecules were included in the model, but with each occupancy reduced to 1/6 or 1/5 to reflect the rotational averaging imposed by the symmetry used to solve capsomer structures.

## QUANTIFICATION AND STATISTICAL ANALYSIS

Reported EM map resolutions are derived from the standard 0.143 cutoff in FSC between two independent half-maps with masks automatically generated in CryoSPARC (Figure S9).<sup>96–98</sup>

Atomic model quality was evaluated by the Phenix<sup>103</sup> Comprehensive validate (cryo-EM) suite including MolProbity.<sup>104</sup> RMSD measurements for structure comparisons were performed using the MatchMaker tool in ChimeraX.<sup>105–107</sup>

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

This work was funded by the National Institutes of Health through grants T32GM008283, U54AI170791, and R37AI116313. Cryo-EM data were collected with the support of staff at the Brookhaven National Laboratory – Laboratory for BioMolecular Structure (LBMS) and the Yale CryoEM Resource. LBMS is supported by the DOE Office of Biological and Environmental Research (KP1607011). The computational resources used are maintained by the Yale Center for Research Computing. We thank Xiong lab members for discussions and support of this work, particularly Dr. M. Meuser, F. Arizaga, and S. Balaji. We also thank Dr. R. Dick for technical advice and suggestions.

## REFERENCES

1. Visseaux B, Damond F, Matheron S, Descamps D, and Charpentier C (2016). Hiv-2 molecular epidemiology. *Infect. Genet. Evol.* 46, 233–240. 10.1016/j.meegid.2016.08.010. [PubMed: 27530215]
2. Clavel F, Guétard D, Brun-Vézinet F, Chamaret S, Rey M-A, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, et al. (1986). Isolation of a new human retrovirus from West African patients with AIDS. *Science* 233, 343–346. 10.1126/science.2425430. [PubMed: 2425430]
3. Hahn BH, Shaw GM, De Cock KM, and Sharp PM (2000). AIDS as a zoonosis: scientific and public health implications. *Science* 287, 607–614. 10.1126/science.287.5453.607. [PubMed: 10649986]
4. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, and Johnson PR (1989). An African primate lentivirus (SIVsm) closely related to HIV-2. *Nature* 339, 389–392. 10.1038/339389a0. [PubMed: 2786147]
5. Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, and Macallan DC (2013). Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. *Rev. Med. Virol.* 23, 221–240. 10.1002/rmv.1739. [PubMed: 23444290]
6. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C-C, Dia MC, Gueye E-H, et al. (1994). Reduced rate of disease development after HIV-2 infection as compared to HIV-1. *Science* 265, 1587–1590. 10.1126/science.7915856. [PubMed: 7915856]
7. Popper SJ, Sarr AD, Travers KU, Guèye-Ndiaye A, Mboup S, Essex ME, and Kanki PJ (1999). Lower Human Immunodeficiency Virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. *J. Infect. Dis.* 180, 1116–1121. 10.1086/315010. [PubMed: 10479138]
8. Dwivedi R, Prakash P, Kumbhar BV, Balasubramaniam M, and Dash C (2024). HIV-1 capsid and viral DNA integration. *mBio* 15, e0021222. 10.1128/mbio.00212-22. [PubMed: 38085100]
9. Chen B (2016). HIV capsid assembly, mechanism, and structure. *Biochemistry* 55, 2539–2552. 10.1021/acs.biochem.6b00159. [PubMed: 27074418]
10. de Silva TI, Cotten M, and Rowland-Jones SL (2008). HIV-2: the forgotten AIDS virus. *Trends Microbiol.* 16, 588–595. 10.1016/j.tim.2008.09.003. [PubMed: 18964021]
11. Temple J, Tripler TN, Shen Q, and Xiong Y (2020). A snapshot of HIV-1 capsid–host interactions. *Curr. Res. Struct. Biol.* 2, 222–228. 10.1016/j.crstbi.2020.10.002. [PubMed: 34113849]
12. Toccafondi E, Lener D, and Negroni M (2021). HIV-1 capsid core: a bullet to the heart of the target cell. *Front. Microbiol.* 12, 652486. 10.3389/fmicb.2021.652486.
13. Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, Bhella D, Gifford RJ, Rixon FJ, and Bieniasz PD (2013). Extreme genetic fragility of the HIV-1 capsid. *PLoS Pathog.* 9, e1003461. 10.1371/journal.ppat.1003461. [PubMed: 23818857]
14. de Silva TI, Leligdowicz A, Carlson J, Garcia-Knight M, Onyango C, Miller N, Yindom L-M, Hué S, Jaye A, Dong T, et al. (2018). HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation. *AIDS* 32, 709–714. 10.1097/QAD.0000000000001753. [PubMed: 29369160]

15. Moncany MLJ, Dalet K, and Courtois PRR (2006). Identification of conserved lentiviral sequences as landmarks of genomic flexibility. *C. R. Biol.* 329, 751–764. 10.1016/j.crv.2006.07.001. [PubMed: 17027636]
16. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, and Elledge SJ (2008). Identification of host proteins required for HIV infection through a functional genomic screen. *Science* 319, 921–926. 10.1126/science.1152725. [PubMed: 18187620]
17. Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, Baumann JG, Wang R, Yuen W, et al. (2010). Flexible use of nuclear import pathways by HIV-1. *Cell Host Microbe* 7, 221–233. 10.1016/j.chom.2010.02.007. [PubMed: 20227665]
18. Price AJ, Fletcher AJ, Schaller T, Elliott T, Lee K, KewalRamani VN, Chin JW, Towers GJ, and James LC (2012). CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. *PLoS Pathog.* 8, e1002896. 10.1371/journal.ppat.1002896. [PubMed: 22956906]
19. Matreyek KA, Yücel SS, Li X, and Engelman A (2013). Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. *PLoS Pathog.* 9, e1003693. 10.1371/journal.ppat.1003693. [PubMed: 24130490]
20. Di Nunzio F, Fricke T, Miccio A, Valle-Casuso JC, Perez P, Souque P, Rizzi E, Severgnini M, Mavilio F, Charneau P, and Diaz-Griffero F (2013). Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication. *Virology* 440, 8–18. 10.1016/j.virol.2013.02.008. [PubMed: 23523133]
21. Buffone C, Martinez-Lopez A, Fricke T, Opp S, Severgnini M, Cifola I, Petiti L, Frabetti S, Skorupka K, Zadrozny KK, et al. (2018). Nup153 unlocks the nuclear pore complex for HIV-1 nuclear translocation in nondividing cells. *J. Virol.* 92, e00648–18. 10.1128/JVI.00648-18. [PubMed: 29997211]
22. Dickson CF, Hertel S, Tuckwell AJ, Li N, Ruan J, Al-Izzi SC, Ariotti N, Sierrecki E, Gambin Y, Morris RG, et al. (2024). The HIV capsid mimics karyopherin engagement of FG-nucleoporins. *Nature* 626, 836–842. 10.1038/s41586-023-06969-7. [PubMed: 38267582]
23. Shen Q, Feng Q, Wu C, Xiong Q, Tian T, Yuan S, Shi J, Bedwell GJ, Yang R, Aiken C, et al. (2023). Modeling HIV-1 nuclear entry with nucleoporin-gated DNA-origami channels. *Nat. Struct. Mol. Biol.* 30, 425–435. 10.1038/s41594-023-00925-9. [PubMed: 36807645]
24. Li W, Singh PK, Sowd GA, Bedwell GJ, Jang S, Achuthan V, Oleru AV, Wong D, Fadel HJ, Lee K, et al. (2020). CPSF6-Dependent Targeting of Speckle-Associated Domains Distinguishes Primate from Nonprimate Lentiviral Integration. *mBio* 11, e02254–20. 10.1128/mBio.02254-20. [PubMed: 32994325]
25. Price AJ, Jacques DA, McEwan WA, Fletcher AJ, Essig S, Chin JW, Halambage UD, Aiken C, and James LC (2014). Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. *PLoS Pathog.* 10, e1004459. 10.1371/journal.ppat.1004459. [PubMed: 25356722]
26. Shen Q, Kumari S, Xu C, Jang S, Shi J, Burdick RC, Levintov L, Xiong Q, Wu C, Devarkar SC, et al. (2023). The capsid lattice engages a bipartite NUP153 motif to mediate nuclear entry of HIV-1 cores. *Proc. Natl. Acad. Sci. USA* 120, e2202815120. 10.1073/pnas.2202815120. [PubMed: 36943880]
27. Li S, Patel JS, Yang J, Crabtree AM, Rubenstein BM, Lund-Andersen PK, Ytreberg FM, and Rowley PA (2022). Defining the HIV capsid binding site of Nucleoporin 153. *mSphere* 7, e0031022. 10.1128/msphere.00310-22. [PubMed: 36040047]
28. Bhattacharya A, Alam SL, Fricke T, Zadrozny K, Sedzicki J, Taylor AB, Demeler B, Pornillos O, Ganser-Pornillos BK, Diaz-Griffero F, et al. (2014). Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. *Proc. Natl. Acad. Sci. USA* 111, 18625–18630. 10.1073/pnas.1419945112. [PubMed: 25518861]
29. Mamede JI, Sitbon M, Battini J-L, and Courgnaud V (2013). Heterogeneous susceptibility of circulating SIV isolate capsids to HIV-interacting factors. *Retrovirology* 10, 77. 10.1186/1742-4690-10-77. [PubMed: 23883001]
30. Lin DH, Zimmermann S, Stuwe T, Stuwe E, and Hoelz A (2013). Structural and functional analysis of the C-terminal domain of Nup358/RanBP2. *J. Mol. Biol.* 425, 1318–1329. 10.1016/j.jmb.2013.01.021. [PubMed: 23353830]

31. Mamede JI, Damond F, Bernardo A.d., Matheron S, Descamps D, Battini J-L, Sitbon M, and Courgnaud V (2017). Cyclophilins and nucleoporins are required for infection mediated by capsids from circulating HIV-2 primary isolates. *Sci. Rep.* 7, 45214. 10.1038/srep45214. [PubMed: 28345672]
32. Meyerson NR, Warren CJ, Vieira DASA, Diaz-Griffero F, and Sawyer SL (2018). Species-specific vulnerability of RanBP2 shaped the evolution of SIV as it transmitted in African apes. *PLoS Pathog.* 14, e1006906. 10.1371/journal.ppat.1006906. [PubMed: 29518153]
33. Franke EK, Yuan HE, and Luban J (1994). Specific incorporation of cyclophilin A into HIV-1 virions. *Nature* 372, 359–362. 10.1038/372359a0. [PubMed: 7969494]
34. Braaten D, Franke EK, and Luban J (1996). Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIVCPZGAB but not group O HIV-1 or other primate immunodeficiency viruses. *J. Virol.* 70, 4220–4227. 10.1128/JVI.70.7.4220-4227.1996. [PubMed: 8676442]
35. Liu C, Perilla JR, Ning J, Lu M, Hou G, Ramalho R, Himes BA, Zhao G, Bedwell GJ, Byeon I-J, et al. (2016). Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. *Nat. Commun.* 7, 10714. 10.1038/ncomms10714. [PubMed: 26940118]
36. Ni T, Gerard S, Zhao G, Dent K, Ning J, Zhou J, Shi J, Anderson-Daniels J, Li W, Jang S, et al. (2020). Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A. *Nat. Struct. Mol. Biol.* 27, 855–862. 10.1038/s41594-020-0467-8. [PubMed: 32747784]
37. Xue G, Yu HJ, Buffone C, Huang S-W, Lee K, Goh SL, Gres AT, Guney MH, Sarafianos SG, Luban J, et al. (2023). The HIV-1 capsid core is an opportunistic nuclear import receptor. *Nat. Commun.* 14, 3782. 10.1038/s41467-023-39146-5. [PubMed: 37355754]
38. Schatz M, Marty L, Ounadjela C, Tong PBV, Cardace I, Mettling C, Milhiet P-E, Costa L, Godefroy C, Pugnière M, et al. (2023). A tripartite complex HIV-1 Tat-Cyclophilin A-capsid protein enables Tat encapsidation that is required for HIV-1 infectivity. *J. Virol.* 97, e0027823. 10.1128/jvi.00278-23. [PubMed: 37129415]
39. Layish B, Goli R, Flick H, Huang S-W, Zhang RZ, Kvaratskhelia M, and Kane M (2024). Virus specificity and nucleoporin requirements for MX2 activity are affected by GTPase function and capsid-CypA interactions. *PLoS Pathog.* 20, e1011830. 10.1371/journal.ppat.1011830. [PubMed: 38512975]
40. Kane M, Rebensburg SV, Takata MA, Zang TM, Yamashita M, Kvaratskhelia M, and Bieniasz PD (2018). Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. *Elife* 7, e35738. 10.7554/eLife.35738. [PubMed: 30084827]
41. Bichel K, Price AJ, Schaller T, Towers GJ, Freund SMV, and James LC (2013). HIV-1 capsid undergoes coupled binding and isomerization by the nuclear pore protein NUP358. *Retrovirology* 10, 81. 10.1186/1742-4690-10-81. [PubMed: 23902822]
42. Price AJ, Marzetta F, Lammers M, Ylinen LMJ, Schaller T, Wilson SJ, Towers GJ, and James LC (2009). Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. *Nat. Struct. Mol. Biol.* 16, 1036–1042. 10.1038/nsmb.1667. [PubMed: 19767750]
43. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabaratz C, Lelièvre J-D, and Manel N (2013). The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. *Immunity* 39, 1132–1142. 10.1016/j.immuni.2013.11.002. [PubMed: 24269171]
44. Jallow S, Lelgadowicz A, Kramer HB, Onyango C, Cotten M, Wright C, Whittle HC, McMichael A, Dong T, Kessler BM, and Rowland-Jones SL (2015). The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated. *Eur. J. Immunol.* 45, 2232–2242. 10.1002/eji.201545451. [PubMed: 26018465]
45. Zuliani-Alvarez L, Govasli ML, Rasaiyaah J, Monit C, Perry SO, Sumner RP, McAlpine-Scott S, Dickson C, Rifat Faysal KM, Hilditch L, et al. (2022). Evasion of cGAS and TRIM5 defines pandemic HIV. *Nat. Microbiol.* 7, 1762–1776. 10.1038/s41564-022-01247-0. [PubMed: 36289397]
46. Kaumanns P, Hagmann I, and Dittmar MT (2006). Human TRIM5α mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants. *Retrovirology* 3, 79. 10.1186/1742-4690-3-79. [PubMed: 17087820]

47. Song H, Nakayama EE, Yokoyama M, Sato H, Levy JA, and Shioda T (2007). A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5 $\alpha$ s. *J. Virol.* 81, 7280–7285. 10.1128/JVI.00406-07. [PubMed: 17475650]
48. Takeuchi JS, Perche B, Migraine J, Mercier-Delarue S, Ponscarne D, Simon F, Clavel F, and Labrosse B (2013). High level of susceptibility to human TRIM5 $\alpha$  conferred by HIV-2 capsid sequences. *Retrovirology* 10, 50. 10.1186/1742-4690-10-50. [PubMed: 23647667]
49. Takeda E, Kono K, Hulme AE, Hope TJ, Nakayama EE, and Shioda T (2015). Fluorescent image analysis of HIV-1 and HIV-2 uncoating kinetics in the presence of old world monkey TRIM5 $\alpha$ . *PLoS One* 10, e0121199. 10.1371/journal.pone.0121199. [PubMed: 25803716]
50. Ohainle M, Kim K, Komurlu Keceli S, Felton A, Campbell E, Luban J, and Emerman M (2020). TRIM34 restricts HIV-1 and SIV capsids in a TRIM5 $\alpha$ -dependent manner. *PLoS Pathog.* 16, e1008507. 10.1371/journal.ppat.1008507. [PubMed: 32282853]
51. Ramalingam VV, Subramanian S, Fletcher GJ, Rupali P, Varghese G, Pulimood S, Jeyaseelan L, Nandagopal B, Sridharan G, and Kannangai R (2019). Interaction of human immunodeficiency virus-1 and human immunodeficiency virus-2 capsid amino acid variants with human tripartite motif 5 $\alpha$  protein SPRY domain and its association with pathogenesis. *Indian J. Med. Microbiol.* 37, 574–583. 10.4103/ijmm.IJMM\_20\_109.
52. Lahaye X, Gentili M, Silvain A, Conrad C, Picard L, Jouve M, Zueva E, Maurin M, Nadalin F, Knott GJ, et al. (2018). NONO detects the nuclear HIV capsid to promote cGAS-mediated innate immune activation. *Cell* 175, 488–501.e22. 10.1016/j.cell.2018.08.062. [PubMed: 30270045]
53. Boswell MT, and Rowland-Jones SL (2019). Delayed disease progression in HIV-2: the importance of TRIM5 $\alpha$  and the retroviral capsid. *Clin. Exp. Immunol.* 196, 305–317. 10.1111/cei.13280. [PubMed: 30773620]
54. Ganser BK, Li S, Klishko VY, Finch JT, and Sundquist WI (1999). Assembly and Analysis of Conical Models for the HIV-1 Core. *Science* 283, 80–83. 10.1126/science.283.5398.80. [PubMed: 9872746]
55. Pornillos O, Ganser-Pornillos BK, and Yeager M (2011). Atomic-level modelling of the HIV capsid. *Nature* 469, 424–427. 10.1038/nature09640. [PubMed: 21248851]
56. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM, Schulten K, Aiken C, and Zhang P (2013). Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. *Nature* 497, 643–646. 10.1038/nature12162. [PubMed: 23719463]
57. Ni T, Zhu Y, Yang Z, Xu C, Chaban Y, Nesterova T, Ning J, Böcking T, Parker MW, Monnie C, et al. (2021). Structure of native HIV-1 cores and their interactions with IP6 and CypA. *Sci. Adv.* 7, eabj5715. 10.1126/sciadv.abj5715. [PubMed: 34797722]
58. Li S, Hill CP, Sundquist WI, and Finch JT (2000). Image reconstructions of helical assemblies of the HIV-1 CA protein. *Nature* 407, 409–413. 10.1038/35030177. [PubMed: 11014200]
59. Deshmukh L, Schwieters CD, Grishaev A, Ghirlando R, Baber JL, and Clore GM (2013). Structure and Dynamics of Full-Length HIV-1 Capsid Protein in Solution. *J. Am. Chem. Soc.* 135, 16133–16147. 10.1021/ja406246z. [PubMed: 24066695]
60. Bayro MJ, Chen B, Yau W-M, and Tycko R (2014). Site-Specific Structural Variations Accompanying Tubular Assembly of the HIV-1 Capsid Protein. *J. Mol. Biol.* 426, 1109–1127. 10.1016/j.jmb.2013.12.021. [PubMed: 24370930]
61. Gres AT, Kirby KA, KewalRamani VN, Tanner JJ, Pornillos O, and Sarafianos SG (2015). X-ray structures of native HIV-1 capsid protein reveal conformational variability. *Science* 349, 99–103. 10.1126/science.aaa5936. [PubMed: 26044298]
62. Mattei S, Glass B, Hagen WJH, Kräusslich H-G, and Briggs JAG (2016). The structure and flexibility of conical HIV-1 capsids determined within intact virions. *Science* 354, 1434–1437. 10.1126/science.aah4972. [PubMed: 27980210]
63. Gupta M, Pak AJ, and Voth GA (2023). Critical mechanistic features of HIV-1 viral capsid assembly. *Sci. Adv.* 9, eadd7434. 10.1126/sciadv.add7434. [PubMed: 36608139]
64. Schirra RT, Dos Santos NFB, Zadrozny KK, Kucharska I, Ganser-Pornillos BK, and Pornillos O (2023). A molecular switch modulates assembly and host factor binding of the HIV-1 capsid. *Nat. Struct. Mol. Biol.* 30, 383–390. 10.1038/s41594-022-00913-5. [PubMed: 36759579]



65. Stacey JCV, Tan A, Lu JM, James LC, Dick RA, and Briggs JAG (2023). Two structural switches in HIV-1 capsid regulate capsid curvature and host factor binding. *Proc. Natl. Acad. Sci. USA* 120, e2220557120. 10.1073/pnas.2220557120. [PubMed: 37040417]
66. Chrystie IL, and Almeida JD (1988). The morphology of human immunodeficiency virus (HIV) by negative staining. *J. Med. Virol.* 25, 281–288. 10.1002/jmv.1890250305. [PubMed: 3171554]
67. KewalRamani VN, and Emerman M (1996). Vpx association with mature core structures of HIV-2. *Virology* 218, 159–168. 10.1006/viro.1996.0176. [PubMed: 8615019]
68. Gea-Mallorquí E, Zablocki-Thomas L, Maurin M, Jouve M, Rodrigues V, Ruffin N, and Benaroch P (2020). HIV-2-infected macrophages produce and accumulate poorly infectious viral particles. *Front. Microbiol.* 11, 1603. 10.3389/fmicb.2020.01603. [PubMed: 32754142]
69. Saad JS, Ablan SD, Ghanam RH, Kim A, Andrews K, Nagashima K, Soheilian F, Freed EO, and Summers MF (2008). Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. *J. Mol. Biol.* 382, 434–447. 10.1016/j.jmb.2008.07.027. [PubMed: 18657545]
70. Matsui T, Kodera Y, Miyauchi E, Tanaka H, Endoh H, Komatsu H, Tanaka T, Kohno T, and Maeda T (2007). Structural role of the secondary active domain of HIV-2 NCp8 in multi-functionality. *Biochem. Biophys. Res. Commun.* 358, 673–678. 10.1016/j.bbrc.2007.04.141. [PubMed: 17511966]
71. Matsui T, Tanaka T, Endoh H, Sato K, Tanaka H, Miyauchi E, Kawashima Y, Nagai-Makabe M, Komatsu H, Kohno T, et al. (2009). The RNA recognition mechanism of human immunodeficiency virus (HIV) type 2 NCp8 is different from that of HIV-1 NCp7. *Biochemistry* 48, 4314–4323. 10.1021/bi802364b. [PubMed: 19334676]
72. Talledge N, Yang H, Shi K, Coray R, Yu G, Arndt WG, Meng S, Baxter GC, Mendonça LM, Castaño-Díez D, et al. (2023). HIV-2 immature particle morphology provides insights into Gag lattice stability and virus maturation. *J. Mol. Biol.* 435, 168143. 10.1016/j.jmb.2023.168143. [PubMed: 37150290]
73. Miyazaki Y, Miyake A, Doi N, Koma T, Uchiyama T, Adachi A, and Nomaguchi M (2017). Comparison of biochemical properties of HIV-1 and HIV-2 capsid proteins. *Front. Microbiol.* 8, 1082. 10.3389/fmicb.2017.01082. [PubMed: 28659897]
74. Summers BJ, Digianantonio KM, Smaga SS, Huang P-T, Zhou K, Gerber EE, Wang W, and Xiong Y (2019). Modular HIV-1 Capsid Assemblies Reveal Diverse Host-Capsid Recognition Mechanisms. *Cell Host Microbe* 26, 203–216.e6. 10.1016/j.chom.2019.07.007. [PubMed: 31415753]
75. Highland CM, Tan A, Ricaña CL, Briggs JAG, and Dick RA (2023). Structural insights into HIV-1 polyanion-dependent capsid lattice formation revealed by single particle cryo-EM. *Proc. Natl. Acad. Sci. USA* 120, e2220545120. 10.1073/pnas.2220545120. [PubMed: 37094124]
76. Dick RA, Zadrozny KK, Xu C, Schur FKM, Lyddon TD, Ricana CL, Wagner JM, Perilla JR, Ganser-Pornillos BK, Johnson MC, et al. (2018). Inositol phosphates are assembly co-factors for HIV-1. *Nature* 560, 509–512. 10.1038/s41586-018-0396-4. [PubMed: 30069050]
77. Mallery DL, Márquez CL, McEwan WA, Dickson CF, Jacques DA, Anandapadamanaban M, Bichel K, Towers GJ, Saiardi A, Böcking T, and James LC (2018). IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis. *Elife* 7, e35335. 10.7554/eLife.35335. [PubMed: 29848441]
78. Renner N, Kleinpeter A, Mallery DL, Albecka A, Rifat Faysal KM, Böcking T, Saiardi A, Freed EO, and James LC (2023). HIV-1 is dependent on its immature lattice to recruit IP6 for mature capsid assembly. *Nat. Struct. Mol. Biol.* 30, 370–382. 10.1038/s41594-022-00887-4. [PubMed: 36624347]
79. Yu A, Lee EMY, Jin J, and Voth GA (2020). Atomic-scale characterization of mature HIV-1 capsid stabilization by inositol hexakisphosphate (IP6). *Sci. Adv.* 6, eabc6465. 10.1126/sciadv.abc6465. [PubMed: 32938668]
80. Ehrlich LS, Agresta BE, and Carter CA (1992). Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. *J. Virol.* 66, 4874–4883. 10.1128/jvi.66.8.4874-4883.1992. [PubMed: 1629958]


81. Gross I, Hohenberg H, Wilk T, Wiegers K, Grättinger M, Müller B, Fuller S, and Kräusslich H-G (2000). A conformational switch controlling HIV-1 morphogenesis. *EMBO J.* 19, 103–113. 10.1093/emboj/19.1.103. [PubMed: 10619849]
82. Ehrlich LS, Liu T, Scarlata S, Chu B, and Carter CA (2001). HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. *Biophys. J.* 81, 586–594. 10.1016/S0006-3495(01)75725-6. [PubMed: 11423440]
83. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, and Yeager M (2009). X-ray structures of the hexameric building block of the HIV capsid. *Cell* 137, 1282–1292. 10.1016/j.cell.2009.04.063. [PubMed: 19523676]
84. Kawamura M, Sakai H, and Adachi A (1994). Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells. *Microbiol. Immunol.* 38, 871–878. 10.1111/j.1348-0421.1994.tb02140.x. [PubMed: 7898386]
85. Jacques DA, McEwan WA, Hilditch L, Price AJ, Towers GJ, and James LC (2016). HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. *Nature* 536, 349–353. 10.1038/nature19098. [PubMed: 27509857]
86. Wei G, Iqbal N, Courouble VV, Francis AC, Singh PK, Hudait A, Annamalai AS, Bester S, Huang S-W, Shkriabai N, et al. (2022). Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection. *Nat. Commun.* 13, 5879. 10.1038/s41467-022-33662-6. [PubMed: 36202818]
87. Vangone A, and Bonvin AM (2015). Contacts-based prediction of binding affinity in protein-protein complexes. *Elife* 4, e07454. 10.7554/eLife.07454. [PubMed: 26193119]
88. Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, and Vangone A (2016). PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. *Bioinformatics* 32, 3676–3678. 10.1093/bioinformatics/btw514. [PubMed: 27503228]
89. Honorato RV, Koukos PI, Jiménez-García B, Tsaregorodtsev A, Verlato M, Giachetti A, Rosato A, and Bonvin AMJJ (2021). Structural biology in the clouds: the WeNMR-EOSC ecosystem. *Front. Mol. Biosci.* 8, 729513. 10.3389/fmolb.2021.729513. [PubMed: 34395534]
90. Caines MEC, Bichel K, Price AJ, McEwan WA, Towers GJ, Willett BJ, Freund SMV, and James LC (2012). Diverse HIV viruses are targeted by a conformationally dynamic antiviral. *Nat. Struct. Mol. Biol.* 19, 411–416. 10.1038/nsmb.2253. [PubMed: 22407016]
91. Yang H, Talledge N, Arndt WG, Zhang W, and Mansky LM (2022). Human immunodeficiency virus type 2 capsid protein mutagenesis reveals amino acid residues important for virus particle assembly. *J. Mol. Biol.* 434, 167753. 10.1016/j.jmb.2022.167753. [PubMed: 35868362]
92. Troyano-Hernández P, Reinosa R, and Holguín Á (2022). HIV capsid protein genetic diversity across HIV-1 variants and impact on new capsid-inhibitor Lenacapavir. *Front. Microbiol.* 13, 854974. 10.3389/fmicb.2022.854974. [PubMed: 35495642]
93. Apetrei C, Hahn B, Rambaut A, Wolinsky S, Brister JR, Keele BF, and Fraser C (2021). HIV Sequence Compendium 2021. Theoretical Biology and Biophysics Group.
94. Henikoff S, and Henikoff JG (1992). Amino acid substitution matrices from protein blocks. *Proc. Natl. Acad. Sci. USA* 89, 10915–10919. 10.1073/pnas.89.22.10915. [PubMed: 1438297]
95. Mastronarde DN (2003). SerialEM: a program for automated tilt series acquisition on Tecnai microscopes using prediction of specimen position. *Microsc. Microanal.* 9, 1182–1183. 10.1017/s1431927603445911.
96. Punjani A, Rubinstein JL, Fleet DJ, and Brubaker MA (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296. 10.1038/nmeth.4169. [PubMed: 28165473]
97. Zivanov J, Nakane T, and Scheres SHW (2019). A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. *IUCrJ* 6, 5–17. 10.1107/S205225251801463X.
98. Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo JM, Sorzano COS, and Vargas J (2021). DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. *Commun. Biol.* 4, 874. 10.1038/s42003-021-02399-1. [PubMed: 34267316]

99. Punjani A, Zhang H, and Fleet DJ (2020). Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat. Methods* 17, 1214–1221. 10.1038/s41592-020-00990-8. [PubMed: 33257830]
100. Grant T, and Grigorieff N (2015). Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6. *Elife* 4, e06980. 10.7554/eLife.06980. [PubMed: 26023829]
101. Emsley P, and Cowtan K (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* 60, 2126–2132. 10.1107/S0907444904019158. [PubMed: 15572765]
102. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010). Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501. 10.1107/S0907444910007493. [PubMed: 20383002]
103. Liebschner D, Afonine PV, Baker ML, Bunkóczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ, et al. (2019). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. *Acta Crystallogr. D Struct. Biol.* 75, 861–877. 10.1107/S2059798319011471. [PubMed: 31588918]
104. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB, et al. (2018). MolProbity: More and better reference data for improved all-atom structure validation. *Protein Sci.* 27, 293–315. 10.1002/pro.3330. [PubMed: 29067766]
105. Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, and Ferrin TE (2018). UCSF ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* 27, 14–25. 10.1002/pro.3235. [PubMed: 28710774]
106. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, and Ferrin TE (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. *Protein Sci.* 30, 70–82. 10.1002/pro.3943. [PubMed: 32881101]
107. Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, and Ferrin TE (2023). UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci.* 32, e4792. 10.1002/pro.4792. [PubMed: 37774136]

**Highlights**

- Determine the capsomere structures that make up the HIV-2 capsid
- Identify distinct contacts that define capsid protein hexamers or pentamers
- Resolve structures of FG-motif peptide-bound HIV-2 capsids, similar to HIV-1





**Figure 1. Assembly and structural analysis of liposome-templated HIV-2 CLPs**

(A) Example cryo-EM micrograph of liposome-templated HIV-2 CLPs (scale bar: 30 nm). Green circles mark example particles picked for three-dimensional (3D) reconstruction. Pink circles mark example particles picked for icosahedral assemblies.

(B) Cryo-EM map of the HIV-2 CA hexamer.

(C) Cryo-EM map of the HIV-2 CA pentamer.

(D) Cryo-EM map of the micelle-templated HIV-2 pentamer icosahedron. Yellow highlights a single CA monomer.




(E) Local resolution map of the micelle-templated HIV-2 pentamer icosahedron.  
(F) Cartoon representation of a CA monomer from the pentamer icosahedron. Sticks correspond to selected residues, with corresponding map densities highlighted on the sides. See also Figures S1–S9 and Table S1.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




**Figure 2. Atomic models of the mature HIV-2 CA lattice assembly**

(A and B) Top and side views of the IP6 density (orchid) in the central pore of the HIV-2 CA hexamer (A; light blue) or pentamer (B; light pink), along with density for residues R18 and K25 (stick). The helices lining the pore are shown in a cartoon representation.

(C) Cartoon representation of the CA protomer in the hexamer (blue) aligned with previous crystal structures of HIV-2 CA NTD<sup>42</sup> (beige) and CTD<sup>72</sup> (green). The insets highlight the structurally conserved salt bridge between GL-AN D97 and R119 (top left), cryo-EM density of the CypA-binding loop (top right), swinging out of the <sub>176</sub>QTD<sub>178</sub> loop of the CTD upon ordered engagement with NTD in the CA lattice (bottom left), and shift of the <sub>58</sub>CVGDH<sub>62</sub> loop of the NTD and adjacent residues to accommodate adjacent protomer contact (light blue; bottom right).

See also Figures S4, S5, and S9 and Tables S1 and S2.



**Figure 3. Unique intra-hexamer/pentamer contacts in the HIV-2 CA lattice**

(A) Alignment of the central pore of HIV-2 models with HIV-1 hexamer (PDB: 4XFX)<sup>61</sup> or HIV-1 pentamer (PDB: 8CKW).<sup>65</sup> The overlapping circles delineate pore sizes as marked by R18 Ca distances.


(B) NTD-NTD intra-oligomer contacts are mediated by the N-terminal 3-helix bundle. Insets highlight the exchange of hydrogen (yellow) or ionic (pink) bonds between helices 2 and 3 to allow the sliding of helix 3 between hexameric and pentameric conformations.

(C) Comparison of the <sub>58</sub>TVGG<sub>61</sub> (HIV-1) and <sub>58</sub>CVGD<sub>61</sub> (HIV-2) loops. While there is a shift between the hexamer and pentamer forms in HIV-2, the loop structures stay similar and comparable to the HIV-1 pentamer <sub>58</sub>TVGG<sub>61</sub> loop conformation. HIV-1 atomic models from PDB: 4XFX<sup>61</sup> (hexamer) and PDB: 8CKW<sup>65</sup> (pentamer).

(D) The NTD-CTD contact area also shifts to accommodate the hexamer/pentamer transition.

(E and F) Side-chain details demonstrating the unique transition of polar contacts between HIV-2 CA NTD (chain 1) residues K31, D61, and Q63 and residues in helix 8 of the adjacent CTD (chain 2).

See also Figure S6.



**Figure 4. Binding of FG peptides to HIV-2 CA hexamers**

(A) Cryo-EM reconstruction of the Nup153 FG-peptide binding to the HIV-2 CA hexamer. Nup153 density and model are in orange, and HIV-2 CA is in cyan.


(B) Cryo-EM reconstruction of the CPSF6 FG-peptide binding to the HIV-2 CA hexamer. CPSF6 density and model are in indigo, and HIV-2 CA is in green.

(C) Details of the atomic model built into the Nup153 FG-peptide density. The inset shows the N-terminal F1415 of the FxFG peptide of Nup153 binds to a less hydrophobic pocket in the HIV-2 CA hexamer with conserved polar residues compared to those in HIV-1 (PDB: 8CKY).<sup>65</sup>

(D) Detailed atomic model built into the CPSF6 peptide density. The inset shows a well-resolved structure for residues Q319 and Q323 interacting with backbone amide groups of HIV-2 CA, which have different conformations in the CPSF6 peptide/HIV-1 CA structures (PDB: 7SNQ).<sup>86</sup>

See also Figures S7–S9 and Tables S1 and S2.





**Figure 5. Mutations implicated in pentamer/hexamer formation among primate lentiviruses**

(A) Phylogenetic tree of selected primate lentiviruses based on CA amino acid sequence similarity.

(B) Multiple sequence alignment of primate lentivirus CA amino acid sequences. Sequences are either from a previously defined group consensus<sup>92</sup> or consensus derived from sequences deposited at the Los Alamos National Laboratory database.<sup>93</sup> Schematic of HIV-1/HIV-2 domain architecture at the top. Residues marked by red asterisks and boxes are specific to the HIV-2/SIV<sub>smm</sub> group. Residues marked by pink crosses and boxes are specific to a broader group of HIV-2-related lentiviruses. Residues marked by blue triangles and boxes are specific changes among the HIV-1-related group. The bottom row displays relative conservation per position based on BLOSUM-80 scoring.<sup>94</sup> Highly conserved positions appear whiter, while more divergent positions appear more pink.

(C) Example of the change at position 39 in HIV-1<sup>61</sup> and HIV-2. Left and central insets highlight the native context of positions 26 and 39 in HIV-1 and HIV-2 with surface representations. The right inset shows aligned HIV-1 and HIV-2 structures with a clash between L26 and M39.



KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and virus strains		
<i>E. coli</i> BL21(DE3)	Lucigen	Cat#60401
Chemicals, peptides, and recombinant proteins		
Luria Broth	Research Products International	Cat#L24400
Terrific Broth	Research Products International	Cat#T5100–5000.0
Isopropyl β-D-1-thiogalactopyranoside (IPTG)	American Bioanalytical	Cat#AB00841-00010
Halt™ Protease Inhibitor Cocktail (100X)	Thermo Scientific	Cat#78430
Trizma® Base	Sigma Aldrich	Cat#T1503
2-Mercaptoethanol (BME)	Alfa Aesar	Cat#J66742-0B
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP)	Thermo Scientific	Cat#20490
Ammonium Sulfate	Thermo Scientific	Cat#J64419.36
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-Hydroxyethyl) piperazine-N'-(2-ethanesulfonic acid) (HEPES)	Sigma Aldrich	Cat#391340
1,2-dioleoyl- <i>sn</i> -glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] nickel salt (DGS-NiNTA)	Avanti Polar Lipids	Cat#790404
1,2-dioleoyl- <i>sn</i> -glycero-3-phosphocholine (DOPC)	Avanti Polar Lipids	Cat#850375
Cholesterol	Thermo Scientific	Cat#A11470
Uranyl Acetate	Electron Microscopy Services	Cat#22400
NuPAGE™ LDS Sample Buffer (4X)	Invitrogen	Cat#NP0008
NuPAGE™ MES SDS Running Buffer (20X)	Invitrogen	Cat#NP0002
SimplyBlue™ SafeStain	Thermo Scientific	Cat#LC6060
Q5® High-Fidelity DNA Polymerase	New England Biolabs	Cat#M0491
Gibson Assembly® Master Mix	New England Biolabs	Cat#E2611
Nup153 peptide (residues 1411–1425/1464–1475)	GenScript	N/A
CPSF6 peptide (residues 313–327)	GenScript	N/A
Recombinant GL-AN HIV-2 CA-GSSHHHHHH	This paper	N/A
Recombinant NL4-3 HIV-1 CA-GSSHHHHHH	This paper	N/A
Deposited data		
EM Map of HIV-2 CA Icosahedron Templated on Liposomes	This paper	EMD-45676
EM Map of HIV-2 CA Hexamer Templated on Liposomes	This paper	EMD-45758
EM Map of HIV-2 CA Pentamer Templated on Liposomes	This paper	EMD-45759
EM Map of HIV-2 CA Hexamer Templated on Liposomes with Nup153 Peptide Bound	This paper	EMD-45760
EM Map of HIV-2 CA Hexamer Templated on Liposomes with CPSF6 Peptide Bound	This paper	EMD-45761
EM Map of HIV-2 CA Pentamer Templated on Liposomes with Nup153 Peptide in Solution	This paper	EMD-45762

REAGENT or RESOURCE	SOURCE	IDENTIFIER
EM Map of HIV-2 CA Pentamer Templated on Liposomes with CPSF6 Peptide in Solution	This paper	EMD-45763
EM Map of HIV-1 CA Pentamer Templated on Liposomes	This paper	EMD-47600
Atomic Model of HIV-2 CA Icosahedron Templated on Liposomes	This paper	PDB: 9CLJ
Atomic Model of HIV-2 CA Hexamer Templated on Liposomes	This paper	PDB: 9CNS
Atomic Model of HIV-2 CA Pentamer Templated on Liposomes	This paper	PDB: 9CNT
Atomic Model of HIV-2 CA Hexamer Templated on Liposomes with Nup153 Peptide Bound	This paper	PDB: 9CNU
Atomic Model of HIV-2 CA Hexamer Templated on Liposomes with CPSF6 Peptide Bound	This paper	PDB: 9CNV
Recombinant DNA		
pET11a GL-AN HIV-2 CA-GSSHHHHHH	This paper	GenBank: PQ189021
Software and algorithms		
SerialEM	Mastronarde et al. <sup>89</sup>	<a href="https://bio3d.colorado.edu/SerialEM/download.html">https://bio3d.colorado.edu/SerialEM/download.html</a>
CryoSPARC	Punjani et al. <sup>90</sup>	<a href="https://guide.cryosparc.com/setup-configuration-and-management/how-to-download-install-and-configure">https://guide.cryosparc.com/setup-configuration-and-management/how-to-download-install-and-configure</a>
Bayesian Motion Correction	Zivanov et al. <sup>91</sup>	N/A
Non-Uniform Refinement	Punjani et al. <sup>93</sup>	N/A
Coot	Emsley et al. <sup>95</sup>	<a href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</a>
Phenix	Liebschner et al. <sup>97</sup>	<a href="https://phenix-online.org/download/">https://phenix-online.org/download/</a>
MolProbity	Williams et al. <sup>98</sup>	N/A
ChimeraX	Goddard et al. <sup>99</sup>	<a href="https://www.cgl.ucsf.edu/chimerax/download.html">https://www.cgl.ucsf.edu/chimerax/download.html</a>
PRODIGY	Xue et al. <sup>82</sup>	<a href="https://rascar.science.uu.nl/prodigy/">https://rascar.science.uu.nl/prodigy/</a>
Other		
Ni-NTA Agarose	Qiagen	Cat#30230
HiTrap® SP HP 5mL	Cytiva	Cat#17115101
HiTrap® SP HP 5mL	Thermo Scientific	Cat#88242
Amicon® Ultra-15 Centrifugal Filter Unit 10 kDa MWCO	Millipore Sigma	Cat#UFC901024
SurePAGE™ Bis-Tris, 10×8, 4–12%, 15 well SDS-PAGE Gels	GenScript	Cat#M00654